When doctors replace a heart valve using a method called transcatheter aortic valve replacement (TAVR), a tissue flap called a leaflet might move and block blood flow to the heart. This can be dangerous. To make TAVR safer, researchers are testing a new tool called TELLTALE, specially made for this procedure.
Key Points:
- Participants will undergo TAVR using the TELLTALE device and be monitored for 90 days.
- Eligible individuals are 21 years or older and at high risk of coronary artery blockage.
- Participation involves hospital visits, tests, questionnaires, and evaluations before and after the procedure.
Adults eligible for the study must be at high risk for coronary artery blockage during TAVR and willing to follow study procedures. They will have tests and answer questions about their health and life quality before and after the procedure. The study lasts for about 90 days with a follow-up in 30 days. If you're interested, ensure you meet the criteria and understand the process involved.
How understandable was the trial content above?
Hard to understand
Easy to understand